Should Health System Specialty Pharmacies (or IDNs) be Included in Market Access Plans?

Leveraging Hospital Market Research to Impact Future Adoption of Cell and Gene Therapies

Which pharmaceutical HUB design is right for you? Insource vs. Outsource vs. Hybrid.

How Pharma & Biotech Manufacturers Can Prepare for COVID-19 HCP Distribution Revenue Cycle Fallout

Track-and-Trace 101

Pharma Reimbursement HUBs: To Audit, or not to Audit?

The 4 Pillars of a Successful Cell and Gene Therapy Launch

Pharmaceutical Distribution Trends to Watch in 2020

5 Essentials for a Successful Advisory Board Meeting

Archbow expands Specialty Distribution expertise with newest team member: Rob Besse

How to Successfully Support Buy-and-Bill Products

5 Considerations for a U.S. Expanded Access Program

The Hottest Topics in Cell and Gene Therapy Today

The Hidden Competitive Advantage: Project Management

Pharmaceutical Patient Support & Access: 6 Trends to Watch

What to know before you migrate a Patient Service Program

Archbow expands cell and gene therapy expertise with newest team member: Paul Furgal

Going global with innovative pharmaceutical contracting and pricing

Why “Demand Chain” is the new “Supply Chain” in Cell and Gene Therapy

5 Steps to Building Your Next Patient Support Services Model